Lilly Sues Two Compounders Over Copies of Weight-loss Drugs

April 2, 2025

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ingredient in its popular weight-loss and diabetes medicines.

This comes after a U.S. federal judge last month refused to allow compounding pharmacies to keep making copies of these drugs in the United States.

Compounders had been allowed to produce hundreds of thousands of doses of copies of obesity drugs only while the FDA said there was a shortage of them.

Lilly said the companies were selling unapproved drugs and making false claims about efficacy and safety.

The drugmaker says it will also send about fifty cease and desist letters to compounders and telehealth companies, asking them to confirm that they have already ceased mass compounding.

Read full coverage at Reuters >>

Find the latest updates on tirzepatide and semaglutide at our resource page: Medical Weight Loss in a Med Spa Practice.

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • AMA Urges HHS to Withdraw Proposal Expanding Access to Certain Unapproved Peptides
    • Health Canada Warns Against Unauthorized Peptides After Bacteria Found in Seized Products
    • FDA Authorizes Clinical Trials Evaluating Lynch Regenerative Medicine’s rhPDGF-BB for Facial Skin Quality and Infraorbital Hollows
    • Hims & Hers Launches Peptides+ for Men
    • Alpha Aesthetics Partners Launches Clinical Education for Platform Practices